<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Anaphylaxis in children and adolescents: The European Anaphylaxis Registry</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-01-21">January 21, 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>MD, MPH</roleName><forename type="first">Linus</forename><forename type="middle">B</forename><surname>Grabenhenrich</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Sabine</forename><surname>D€ Olle</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Anne</forename><surname>Moneret-Vautrin</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Alice</forename><surname>K€ Ohli</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Lars</forename><surname>Lange</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Thomas</forename><surname>Spindler</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Dermatology and Allergology</orgName>
								<orgName type="laboratory">Pediatric Pneumology and Allergology</orgName>
								<orgName type="institution">Lungenzentrum S€ ud-West</orgName>
								<address>
									<settlement>Wangen</settlement>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="institution">Ludwig-Maximilian-Universit€ at</orgName>
								<address>
									<settlement>Munich</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Franziska</forename><surname>Ru€ Eff</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Katja</forename><surname>Nemat</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Paediatrics and Child Health</orgName>
								<orgName type="laboratory">Pediatric Pneumology and Allergology</orgName>
								<orgName type="institution">Kinderzentrum Dresden-Friedrich-stadt</orgName>
								<address>
									<settlement>Dresden</settlement>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department" key="dep1">Allergy Department</orgName>
								<orgName type="department" key="dep2">Department of Derma-tology</orgName>
								<orgName type="institution" key="instit1">University College Cork</orgName>
								<orgName type="institution" key="instit2">University of Athens</orgName>
								<orgName type="institution" key="instit3">University Hospital Basel</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Ioana</forename><surname>Maris</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Eirini</forename><surname>Roumpedaki</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Kathrin</forename><surname>Scherer</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Hagen</forename><surname>Ott</surname></persName>
							<affiliation key="aff8">
								<orgName type="laboratory">Pediatric Dermatology and Allergology</orgName>
								<orgName type="institution">Children&apos;s Hospital Auf der Bult</orgName>
								<address>
									<settlement>Hannover</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Thomas</forename><surname>Reese</surname></persName>
							<affiliation key="aff9">
								<orgName type="institution" key="instit1">Rheine Kinderklinik</orgName>
								<orgName type="institution" key="instit2">Mathias-Spital</orgName>
								<address>
									<settlement>Rheine</settlement>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department" key="dep1">Clinical Centre of Allergology</orgName>
								<orgName type="department" key="dep2">Department of Dermatology</orgName>
								<orgName type="department" key="dep3">Allergy Department</orgName>
								<orgName type="institution" key="instit1">University Hospital Alexandrovska/Medical Univer-sity Sofia</orgName>
								<orgName type="institution" key="instit2">Paracelsus Medizinische Privatuniversit€ at Salzburg</orgName>
								<orgName type="institution" key="instit3">Hospital Clinico San Carlos IdISSC</orgName>
								<address>
									<settlement>Madrid</settlement>
								</address>
							</affiliation>
							<affiliation key="aff11">
								<orgName type="department" key="dep1">Department of Immunology, Rheumatology and Allergy</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine/Allergy Unit</orgName>
								<orgName type="institution" key="instit1">Medical University of Lodz</orgName>
								<orgName type="institution" key="instit2">University Hospital Ospedali Riu-niti</orgName>
								<address>
									<settlement>Ancona</settlement>
								</address>
							</affiliation>
							<affiliation key="aff12">
								<orgName type="department">Icahn School of Medicine at Mount Sinai</orgName>
								<address>
									<settlement>New York</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Tihomir</forename><surname>Mustakov</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Roland</forename><surname>Lang</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Montserrat</forename><surname>Fernandez-Rivas</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Marek</forename><forename type="middle">L</forename><surname>Kowalski</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Maria</forename><forename type="middle">B</forename><surname>Bil</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jonathan</forename><surname>O'</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">B</forename><surname>Hourihane</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Nikolaos</forename><forename type="middle">G</forename><surname>Papadopoulos</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Kirsten</forename><surname>Beyer</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Antonella</forename><surname>Muraro</surname></persName>
						</author>
						<author role="corresp">
							<persName><roleName>MD</roleName><forename type="first">Margitta</forename><surname>Worm</surname></persName>
							<email>margitta.worm@charite.de</email>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="institution">Zurich and Basel</orgName>
								<address>
									<settlement>Berlin, Bonn, Wangen, Munich, Hannover, Rheine, Dresden, Germany, Nancy, Athens, Salzburg, Madrid, Lodz, Ancona and Padua, Italy, New York</settlement>
									<region>Cork, Sofia, NY</region>
									<country>France, Switzerland, Ireland, Greece, Bulgaria, Austria, Spain, Poland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="department">Institute for Social Medicine, Epidemiology and Health Economics</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of Dermatology and Allergy</orgName>
								<orgName type="department" key="dep2">Department of Pediatric Pneumol-ogy and Immunology</orgName>
								<orgName type="institution">Allergy Vigilance Network</orgName>
								<address>
									<settlement>Charit e -Universit€ atsmedizin Berlin</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Division of Allergology</orgName>
								<orgName type="department" key="dep2">Department of Pediatrics</orgName>
								<orgName type="institution" key="instit1">University Hospital Nancy</orgName>
								<orgName type="institution" key="instit2">University Children&apos;s Hospital Zurich</orgName>
								<orgName type="institution" key="instit3">St Marien-Hospital</orgName>
								<address>
									<settlement>Bonn</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff13">
								<orgName type="department">Department of Mother and Child Health</orgName>
								<orgName type="institution">Padua General University Hospital</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff14">
								<address>
									<settlement>Dublin</settlement>
									<country key="IE">Ireland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff15">
								<orgName type="department">Department of Dermatology and Allergy</orgName>
								<address>
									<addrLine>Charit eplatz 1</addrLine>
									<postCode>10117</postCode>
									<settlement>Charit e -Universit€ atsmedizin Berlin, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Anaphylaxis in children and adolescents: The European Anaphylaxis Registry</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-01-21">January 21, 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">B69B648BB4F4D9E26B92116412C4683D</idno>
					<idno type="DOI">10.1016/j.jaci.2015.11.015</idno>
					<note type="submission">Received for publication July 24, 2015; revised October 9, 2015; accepted for publication November 10, 2015.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:39+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Anaphylaxis</term>
					<term>arthropod venoms</term>
					<term>drug hypersensitivity</term>
					<term>epinephrine</term>
					<term>food hypersensitivity</term>
					<term>registries</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background: Anaphylaxis in children and adolescents is a potentially life-threatening condition.</s><s>Its heterogeneous clinical presentation and sudden occurrence in virtually any setting without warning have impeded a comprehensive description.</s><s>Objective: We sought to characterize severe allergic reactions in terms of elicitors, symptoms, emergency treatment, and longterm management in European children and adolescents.</s><s>Methods: The European Anaphylaxis Registry recorded details of anaphylaxis after referral for in-depth diagnosis and counseling to 1 of 90 tertiary allergy centers in 10 European countries, aiming to oversample the most severe reactions.</s><s>Data were retrieved from medical records by using a multilanguage online form.</s><s>Results: Between July 2007 and March 2015, anaphylaxis was identified in 1970 patients younger than 18 years.</s><s>Most incidents occurred in private homes (46%) and outdoors (19%).</s><s>One third of the patients had experienced anaphylaxis previously.</s><s>Food items were the most frequent trigger (66%), followed by insect venom (19%).</s><s>Cow's milk and hen's egg were prevalent elicitors in the first 2 years, hazelnut and cashew in preschool-aged children, and peanut at all ages.</s><s>There was a continuous shift from food-to insect venom-and drug-induced anaphylaxis up to age 10 years, and there were few changes thereafter.</s><s>Vomiting and cough were prevalent symptoms in the first decade of life, and subjective symptoms (nausea, throat tightness, and dizziness) were prevalent later in life.</s><s>Thirty percent of cases were lay treated, of which 10% were treated with an epinephrine autoinjector.</s><s>The fraction of intramuscular epinephrine in professional emergency treatment increased from 12% in 2011 to 25% in 2014.</s><s>Twenty-six (1.3%) patients were either admitted to the intensive care unit or had grade IV/ fatal reactions.</s><s>Conclusions: The European Anaphylaxis Registry confirmed food as the major elicitor of anaphylaxis in children, specifically hen's egg, cow's milk, and nuts.</s><s>Reactions to insect venom were seen more in young adulthood.</s><s>Intensive care unit admissions and grade IV/fatal reactions were rare.</s><s>The registry will serve as a systematic foundation for a continuous description of this multiform condition.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>2]<ref type="bibr" target="#b53">[3]</ref> Typical elicitors and the clinical presentation of anaphylaxis in children and adolescents were shown to be different from those in adults, <ref type="bibr" target="#b54">4</ref> calling for specific research and targeted guideline development for a pediatric population. <ref type="bibr" target="#b55">5,</ref><ref type="bibr" target="#b56">6</ref></s><s>ncreasing frequencies of allergic diseases have been observed over recent decades, but there is considerable uncertainty in whether this reflects true variations in disease frequency or differences in perception, labeling, and diagnostic habits. <ref type="bibr" target="#b57">7</ref></s><s>Little is known about the occurrence of severe allergic reactions and time trends on a population level, <ref type="bibr" target="#b58">[8]</ref><ref type="bibr" target="#b59">[9]</ref><ref type="bibr" target="#b60">[10]</ref> and even less is known for pediatric anaphylaxis. <ref type="bibr" target="#b61">11,</ref><ref type="bibr" target="#b62">12</ref></s><s>ood items are the most common triggers of severe allergic reactions in childhood, with some allergens, such as cow's milk and hen's egg, specific to young ages.</s><s>However, age-dependent distributions have not been published for adequately large populations to account for less frequent causes.</s><s>The clinical picture of anaphylaxis in children, especially that in infants, is different from that in adults. <ref type="bibr" target="#b54">4,</ref><ref type="bibr" target="#b63">13</ref></s><s>This varied clinical picture reflects differences in allergen absorption, a developing immune system, and lack of preschoolers' ability to talk about subjective symptoms.</s><s>Interpretation of diagnostic tests (eg, tryptase measurement) is valid only in light of age-dependent reference values and experience in pediatric allergology.</s><s>Confirming the causal role of a suspected elicitor can become a tedious venture, even more so in children.</s></p><p><s>Emergency treatment, long-term management, and counseling are supported by current guidelines <ref type="bibr" target="#b52">2,</ref><ref type="bibr" target="#b64">14</ref> but are only partly adapted to pediatric settings. <ref type="bibr" target="#b65">15</ref></s><s>For example, there is a long-standing debate about the application and dose of epinephrine as the first-line treatment for anaphylaxis. <ref type="bibr" target="#b66">16</ref></s><s>Reactions initially treated by a layperson rely on epinephrine autoinjectors, which are also available for younger patients but not for infants. <ref type="bibr" target="#b67">17</ref></s><s>Implementation of treatment recommendations has been assessed in the general population, <ref type="bibr" target="#b68">18</ref> but data on emergency management in children and adolescents are lacking.</s><s>Counseling to reduce the risk of recurrent reactions and emergency drug prescriptions could be tailored based on age-specific distributions of comorbidities and cofactors, such as asthma or physical exercise.</s></p><p><s>Based on data collected in the European Anaphylaxis Registry from 2007 to 2015, <ref type="bibr" target="#b69">19</ref> the aim of this analysis was to show data on the most severe allergic reactions occurring in children and adolescents.</s><s>This large-scale survey comprises data on elicitors, symptoms, emergency treatment, and long-term management from 10 countries.</s><s>The survey allows guideline adherence to be traced by comparing treatment habits over 8 consecutive years.</s><s>The overall goal was to improve the timely recognition, emergency management, and prevention of recurrent reactions by disseminating knowledge of age-dependent distributions of pediatric anaphylaxis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Setting and design</head><p><s>The European Anaphylaxis Registry collected information on anaphylactic reactions through a Web-based data entry system.</s><s>Data for the current analysis were provided by tertiary referral centers specialized in pediatric allergology, dermatology, or both in Germany, France, Switzerland, Ireland, Greece, Austria, Spain, Bulgaria, Italy, and Poland.</s><s>The study was approved by the Ethics Committee at Charit e -Universit€ atsmedizin Berlin (the coordinating center) and by the local ethics committees in all participating countries.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Participants</head><p><s>Children who experienced anaphylaxis were referred to the participating specialized clinics for in-depth diagnosis, counseling, and, if possible, specific immunotherapy.</s><s>On their first visit, parents were asked to provide written informed consent to allow registration of the child's medical history and reaction details in the database after completion of the diagnostic workup.</s><s>The study centers were asked to enter their most severe cases, usually with circulatory or respiratory symptoms, but milder anaphylaxis could be recorded as well.</s><s>Fatal anaphylaxis, known from either counseling of previous reactions in the referral center or from an emergency physician's notification, could be recorded with the parents' consent as well.</s><s>Database entries were included if the sex of the child and the year of reaction were specified and the age at reaction was less than 18 years.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data source and handling</head><p><s>The online data entry system comprised a German questionnaire for Germany, Austria, and Switzerland; a French version for centers in France; and an English version for all other participating countries.</s><s>The questionnaire was initially developed and piloted in the German Anaphylaxis Registry <ref type="bibr" target="#b70">20,</ref><ref type="bibr" target="#b71">21</ref> and translated/back-translated for international use.</s><s>The questionnaire was refined through yearly updates, with new items introduced based on expert judgment.</s><s>Interrater reliability was assessed by using repeated data entry by 2 independent professionals.</s><s>Data collected through questionnaire versions 2 to 6 (n 5 134, 219, 167, 689, and 761) with entry dates from July 2007 to March 2015 were used.</s><s>Trained professionals in each study center retrieved data retrospectively from the medical records, including laboratory measures and emergency protocols.</s><s>Raw study data were stored with pseudonyms on a server at Charit e -Universit€ atsmedizin Berlin.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Variables</head><p><s>Specific areas covered have been reported earlier, <ref type="bibr" target="#b72">22</ref> and the online version can be accessed through www.anaphylaxie.net.</s><s>Age at reaction was categorized in 3 strata: preschoolers (0-5 years), schoolchildren (6-12 years), and adolescents (13-17 years).</s><s>Assuming primary documentation habits to differ randomly, most variables were reported as a fraction of valid answers by item (comorbidities, cofactors, details of previous reactions, symptoms and severity, emergency treatment, and long-term management).</s><s>Therefore the denominator used for calculating percentages might slightly vary from the column totals shown.</s><s>The location of reaction was reported as a fraction of all cases, assuming missing answers to represent categories not presented as default.</s><s>Elicitors were assessed by using a comprehensive list of typical foods, insect venoms, drugs, and other less frequently expected causes of allergic reaction, such as latex or allergen immunotherapy.</s><s>Rare food items specified as free text entries were reported within the group of food elicitors.</s><s>The diagnostic certainty of the causal agent was documented at the 2 levels known versus suspected based on the local allergy specialist's individual appraisal, without specifying reasons for their decision.</s><s>Symptoms documented through free text were manually assigned to default answer categories, where reasonable.</s><s>Severity was graded retrospectively based on the 4 levels of symptom profiles proposed by Ring and Messmer 23 : grade II with involvement of at least 2 organ systems, grade III with signs of circulatory and/or respiratory failure/shock, and grade IV with circulatory or respiratory arrest.</s><s>The criteria for selection of the most severe cases were (1) a known elicitor with grade III symptoms admitted to an intensive care unit, (2) grade IV symptoms, or (3) fatal reactions.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistics</head><p><s>Cleaning and analysis of data were carried out by using the SAS 9.4 system (SAS Institute, Cary, NC).</s><s>Stratified analysis of frequencies was used to describe documented characteristics.</s><s>Individual queries were performed in an attempt to complete missing data.</s><s>All variables other than age at reaction, date of birth, and sex were allowed to remain missing by item because the registry aimed to cover only information documented in the underlying records.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study centers and participants</head><p><s>The European Anaphylaxis Registry collected data on 1970 children from 90 study centers in 10 countries: Germany (n 5 1040), France (n 5 321), Switzerland (n 5 297), Ireland (n 5 95), Greece (n 5 86), Austria (n 5 59), Spain (n 5 36), Bulgaria (n 5 25), Italy (n 5 6), and Poland (n 5 5).</s><s>Six hundred ninety-two (35%) were female, with a higher female proportion in adolescents (43%).</s><s>All ages (in 1-year intervals) were represented similarly, except for infants (&lt;1 year, n 5 18) and 1-year-old children (n 5 246).</s><s>Of the 1970 children, 861 (44%) were preschoolers (&lt;6 years), 655 (33%) were children between 6 and 12 years of age, and 454 (23%) were adolescents (13-17 years)  with anaphylaxis.</s></p><p><s>In their recent medical history the following respiratory allergies were reported mainly for children between 6 and 12 years of age and for adolescents: asthma (30% and 22%, respectively) and allergic rhinitis (29% and 27%, respectively).</s><s>Atopic dermatitis was predominant in preschoolers (41%).</s><s>Other allergy-related conditions were not dependent on age: urticaria (1.1%), food hypersensitivity not related to the incriminated elicitor (0.5%), and mastocytosis (0.2%).</s><s>Short-term factors (cofactors) potentially influencing allergenic disposition were physical exercise (21%) and medication other than that suspected as the actual elicitor (5%), both of which were not specified in detail in the registry.</s><s>Most reactions occurred in private homes (46%) and outdoor locations (countryside and urban, 19%), followed by school or working environments (9%).</s></p><p><s>Six hundred four (33%) children had allergic reactions before occurrence of the recorded incident.</s><s>Of these, 10% reported at least 1 milder reaction, and 42% reported more than 1 previous event of any severity.</s><s>The elicitor was already known and diagnosed before the recorded reaction in 71% of the recurrent cases.</s><s>The characteristics of previous reactions were based on parent's report only and did not differ by age (Table <ref type="table" target="#tab_0">I</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Elicitors</head><p><s>Severe allergic reactions were caused by food items in 1291 (66%) of 1970 of the patients, followed by 381 (19%) cases of insect venom and 101 (5%) cases of drug anaphylaxis.</s><s>The cause was ascertained by a local allergy specialist in 1565 (79%) cases and was based on history, laboratory measures, and diagnostic procedures.</s><s>Until school enrollment (&lt;6 years), foods were the predominating elicitors reported (88%), and cow's milk (n 5 120) and hen's egg (n 5 115) were the predominating elicitors reported in the first 2 years.</s><s>Most of the reactions to cashew (66 of all 87 reported) and hazelnut (57 of all 86 reported) occurred in the preschool-aged children.</s><s>Peanut was an elicitor for anaphylaxis from infancy to young adulthood (overall n 5 325).</s><s>Insect venom-induced anaphylaxis appeared in early school age and continued until 17 years of age, with yellow jacket (overall n 5 191) and bee stings (overall n 5 161) responsible for the Cofactors reported only infrequently are not shown: menstruation (n 5 10) and alcohol (n 5 8).</s><s>*In addition to the food or foods incriminated to cause the anaphylaxis reported.</s></p><p><s>As judged by the allergist counseling the family/child and not specified in detail by questionnaire items.</s><s>majority of cases.</s><s>Drugs were elicitors primarily for adolescents, and analgesics (n 5 41) and antibiotics (n 5 22) were the most common causal agents.</s><s>Fifty cases of anaphylaxis were attributed to specific immunotherapy (Table <ref type="table" target="#tab_1">II</ref>).</s><s>There was a continuous shift of elicitors from foods to insect venom and drugs from infancy until approximately 10 years of age, after which the pattern of elicitors remained relatively stable (Fig <ref type="figure">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Symptoms</head><p><s>The skin was involved in almost all children (92%).</s><s>The following specific skin symptoms occurred similarly across all ages (overall percentages): angioedema (53%), urticaria (62%), pruritus (37%), and erythema/flush (29%; details are provided in Table <ref type="table">E1</ref> in this article's Online Repository at www.jacionline.</s><s>org).</s><s>Gastrointestinal symptoms accompanied 45% of anaphylactic reactions, with vomiting (overall 27%) dominating in the preschool ages and nausea (overall 15%) increasing into Most reactions were categorized as grade II (45%, &gt; _2 organ systems) or grade III (47%, 2 organ systems severely involved), with similar distributions in age strata.</s><s>The time between exposure and onset of symptoms was usually less than 10 minutes (58%), but 8% of the patients reported a delayed reaction with an interval of more than 1 hour.</s><s>Seventy-seven (5%) children experienced biphasic reactions.</s><s>Of these, 42% had the second reaction more than 12 hours after the first reaction (see Table <ref type="table">E1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Emergency treatment</head><p><s>Five hundred sixty-two (30%) children were initially cared for by a layperson, of whom 5% were nursery or school teachers, and 10% of the children, mainly those older than 12 years (37%), administered emergency drugs themselves.</s><s>The application of an epinephrine autoinjector increased with age from 10% (lay treated) in preschoolers to 19% in adolescents.</s><s>An additional 14% of the patients had an autoinjector prescription but did not carry it or failed to apply it.</s><s>Similar across all age groups, lay treatment included antihistamine (78%) and corticosteroid tablets (52%), as well as b 2 -agonist inhalers (28%).</s></p><p><s>Emergency treatment was administered by a health professional in 1363 (72%) of the children; of these, 38% were treated by an emergency physician.</s><s>With few differences between age groups, professional treatment included epinephrine (28%), antihistamines (76%), corticosteroids (82%), or b 2 -agonists (23%).</s><s>Second-line treatment (eg, additional doses or other drugs not used for initial management, usually on failure to improve after first-line treatment) was reported in 19% of professionally treated children, and 9% of the children received a second dose of epinephrine.</s><s>Three hundred ninety-four children were admitted to a hospital, of whom 6% (25) were treated in an intensive care unit (Table <ref type="table" target="#tab_3">III</ref>).</s><s>When treated by a health professional, epinephrine was mainly administered intramuscularly, with an increasing proportion from 12% in 2011-2012 to 25% in 2014-2015 (Fig 3).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Diagnosis and counseling</head><p><s>Similar in all age groups, the diagnostic workup included skin testing (72%, of which 85% of results were positive) and specific IgE (89%, of which 91% of results were positive) and tryptase (34%, of which 6% of results were &gt; _11.5 ng/mL) measurements.</s><s>The current questionnaire did not collect laboratory test results.</s><s>Allergen immunotherapy was started in 73% of cases of Hymenoptera-induced venom anaphylaxis.</s><s>Almost all children received a prescription for emergency drugs (91%), mainly including an epinephrine autoinjector (90%), antihistamines (98%), and corticosteroids (91%, Table <ref type="table" target="#tab_4">IV</ref>).</s><s>Specifically, not receiving an epinephrine autoinjector prescription differed by elicitor (food, 10%; insects, 5%) and severity (grade I, 23%; grade II, 11%; grade III, 7%).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Life-threatening and fatal reactions</head><p><s>Twenty-six (1.3%) of the 1970 children experienced life-threatening or fatal reactions: 11 experienced grade III symptoms and intensive care unit admission, 10 experienced grade IV symptoms, and 5 of the patients died.</s><s>The most severe anaphylactic reactions were seen in all age groups.</s><s>The distribution of elicitors in the entire registry resembled that in the group of patients with the most severe reactions.</s><s>In this group the most frequently reported causes of anaphylaxis, such as cow's milk, hazelnut, cashew, peanut, and insect venom (Table <ref type="table" target="#tab_1">II</ref>), were also responsible for the most severe reactions; an exception was hen's egg allergy, which never led to life-threatening anaphylaxis despite being reported in 134 children.</s><s>Eight children in this group were initially treated by a layperson in the family or a teacher, 4 of whom used an epinephrine autoinjector.</s><s>Eight cases described previous reactions to the same allergen, usually with milder symptoms (Table <ref type="table" target="#tab_5">V</ref>). <ref type="bibr" target="#b73">23</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Key results</head><p><s>With 1970 patients, this is the first large-scale description of pediatric anaphylaxis.</s><s>More data were collected on boys (about two thirds) than on girls, but the European Anaphylaxis Registry covered all age groups, including a sparsely populated first year of life.</s><s>Although sex differences have been described for several allergic diseases, <ref type="bibr" target="#b74">24</ref> the sampling scheme used here does not support the interpretation of skewed distributions of age, sex, or other baseline information.</s><s>One in 3 children experienced previous reactions and usually knew about the specific trigger.</s></p><p><s>In preschoolers, food was almost the only elicitor for anaphylaxis, dominated by cow's milk and hen's egg; peanut allergy was present in all ages.</s><s>With the large data set of the current study, it was possible to describe a continuous shift from food-induced toward insect venom-and drug-induced anaphylaxis until 10 years of age, and few changes in trigger patterns were found thereafter.</s><s>The predominance of food elicitors was in line with other data, such as from the United States. <ref type="bibr" target="#b63">13</ref></s><s>The signs and symptom patterns varied considerably by age, with vomiting and coughing limited to the first decade of life.</s><s>In contrast, subjective symptoms, such as nausea, throat tightness, or dizziness, appeared more frequently into adolescence.</s><s>Similar patterns have been described in a smaller sample of food-induced anaphylaxis treated in a US emergency department. <ref type="bibr" target="#b75">25</ref></s><s>ne in 3 anaphylactic reactions was initially treated by a layperson, including self-application of emergency drugs, which was rarely observed before adolescence.</s><s>The use of epinephrine autoinjectors increased with age but reached only approximately 1 in 5 adolescents treated by a layperson.</s><s>A similar proportion of children were already prescribed an autoinjector but either did not carry or apply the device.</s><s>There is strong expert opinion toward including epinephrine as a first-line treatment of severe allergic reactions.</s><s>This opinion is reflected in the current guidelines 2 but is not supported by clear evidence. <ref type="bibr" target="#b66">16</ref></s><s>In a community-based survey uncertainty about the severity of the reaction, fear of side effects, and difficulties deciding which drugs to use (eg, steroids) were identified as reasons for not applying autoinjectors, despite having them at hand. <ref type="bibr" target="#b76">26</ref></s><s>From our data, 10% of children did not receive a prescription for an autoinjector.</s><s>In addition to teaching  and training, availability of other noninvasive application routes might increase the application of epinephrine by laypersons.</s><s>For example, sublingual epinephrine-containing microcrystals are currently being tested. <ref type="bibr" target="#b77">27</ref></s><s>rofessional first aid treatment was mainly administered by emergency physicians not specifically trained to tailor treatment options by age.</s><s>Approximately one in 3 children received epinephrine, irrespective of age.</s><s>A similar proportion was documented for adults in other populations. <ref type="bibr" target="#b76">26</ref></s><s>The fraction of children who received epinephrine intramuscularly doubled during the observation period, which might reflect changes in professional education and the development of harmonized treatment guidelines. <ref type="bibr" target="#b52">2</ref> Despite the European Anaphylaxis Registry being targeted to collect information only on severe allergic reactions, only approximately 1% of cases were treated in the intensive care unit, had grade IV reactions, or led to the death of the child.</s><s>Such reactions were seen in all age groups and caused by the same elicitors typically seen in the whole sample.</s><s>There does not seem to be a specific age or a specific cause of life-threatening anaphylaxis, limiting the prediction of severe reactions.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Strength and limitations</head><p><s>The large number of participating countries, centers, and patients allowed a stratified report of reaction details by age, despite anaphylaxis being a relatively rare incident.</s><s>The online assessment tool used in this Registry, which was developed in the German-speaking registry, iteratively refined and piloted, <ref type="bibr" target="#b69">19</ref> covered all major aspects of anaphylaxis, including elicitors, symptoms, emergency treatment, and long-term management.</s><s>The study data were limited to what was initially documented in a nonstandardized way during the clinical visit because data entry was based on medical records.</s><s>Participating centers were asked to keep the registry's questionnaire items in mind while taking the medical history to improve the details of data recorded in the clinical routine.</s><s>The parents' decision to seek further advice might be linked to symptom awareness or perceived severity, which could lead to a skewed distribution of the study population.</s><s>Such self-referral might limit the study's external validity.</s><s>On the other hand, collecting data in tertiary centers allowed identification of an adequately large number of cases to support the analysis of small subgroups of, for example, age or specific elicitors.</s><s>Of note, the relative frequency of fatal reactions reported here is not a valid estimate of the fatality rate because most deaths attributed to an allergic cause are not expected to come to a tertiary center's attention.</s><s>Therefore the actual occurrence of fatal anaphylaxis is probably more frequent.</s><s>This registry collected 1-time data only.</s><s>Measures of frequency cannot be estimated from this registry because it did not aim to represent the general population and did not clearly define the study base.</s><s>Different participation of countries does not allow direct comparison of case numbers.</s><s>However, this study excels in its comparison of patterns of elicitors or emergency treatment habits by age, year, or region.</s><s>It applied harmonized methodology in all study centers, as necessary for sound comparisons. <ref type="bibr" target="#b60">10</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head><p><s>This is a large report of anaphylaxis in children and adolescents, including an age-dependent illustration of typical elicitors, symptoms, and emergency treatment.</s><s>This study might serve as a robust knowledge base for how and where severe allergic reactions in the first years of life occur and how they are currently being treated.</s><s>For example, analyzing time trends in epinephrine use, the registry was able to document a considerable</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>FIG 3 .</head><label>3</label><figDesc><div><p><s>FIG 3. Proportion of children receiving epinephrine and route of administration by year of reaction referring to those treated by a professional and with at least grade II reactions in 2009-2014 (n 5 1086).</s><s>If a child received epinephrine through more than 1 route, intramuscular is reported before the other 2, and intravenous is reported before inhalation.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>TABLE I .</head><label>I</label><figDesc><div><p><s>Baseline data, reaction circumstances, and previous reactions by age group</s></p></div></figDesc><table><row><cell></cell><cell cols="2">Preschoolers, &lt;6 y</cell><cell cols="2">Children, 6-12 y</cell><cell cols="2">Adolescents, 13-17 y</cell><cell>All</cell><cell></cell></row><row><cell></cell><cell>No.</cell><cell>Percent</cell><cell>No.</cell><cell>Percent</cell><cell>No.</cell><cell>Percent</cell><cell>No.</cell><cell>Percent</cell></row><row><cell>Total</cell><cell>861</cell><cell></cell><cell>655</cell><cell></cell><cell>454</cell><cell></cell><cell>1970</cell><cell></cell></row><row><cell>Girls</cell><cell>291</cell><cell>33.8</cell><cell>204</cell><cell>31.1</cell><cell>197</cell><cell>43.4</cell><cell>692</cell><cell>35.1</cell></row><row><cell>Comorbidities (recent medical history)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Allergic rhinitis</cell><cell>109</cell><cell>13.0</cell><cell>181</cell><cell>28.5</cell><cell>117</cell><cell>26.6</cell><cell>407</cell><cell>21.2</cell></row><row><cell>Asthma</cell><cell>150</cell><cell>17.8</cell><cell>190</cell><cell>29.9</cell><cell>98</cell><cell>22.3</cell><cell>438</cell><cell>22.9</cell></row><row><cell>Atopic dermatitis</cell><cell>348</cell><cell>41.4</cell><cell>110</cell><cell>17.3</cell><cell>45</cell><cell>10.2</cell><cell>503</cell><cell>26.3</cell></row><row><cell>Urticaria</cell><cell>10</cell><cell>1.2</cell><cell>7</cell><cell>1.1</cell><cell>4</cell><cell>0.9</cell><cell>21</cell><cell>1.1</cell></row><row><cell>Mastocytosis</cell><cell>1</cell><cell>0.1</cell><cell>1</cell><cell>0.2</cell><cell>1</cell><cell>0.2</cell><cell>3</cell><cell>0.2</cell></row><row><cell>Food hypersensitivity*</cell><cell>1</cell><cell>0.2</cell><cell>4</cell><cell>0.9</cell><cell>2</cell><cell>0.7</cell><cell>7</cell><cell>0.5</cell></row><row><cell>Cofactors (preceding the reaction)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Physical exercise</cell><cell>130</cell><cell>16.4</cell><cell>147</cell><cell>25.2</cell><cell>104</cell><cell>25.4</cell><cell>381</cell><cell>21.3</cell></row><row><cell>Psychological stress</cell><cell>14</cell><cell>1.6</cell><cell>16</cell><cell>2.4</cell><cell>17</cell><cell>3.7</cell><cell>47</cell><cell>2.4</cell></row><row><cell>Medication</cell><cell>27</cell><cell>3.2</cell><cell>37</cell><cell>5.6</cell><cell>40</cell><cell>9.0</cell><cell>104</cell><cell>5.3</cell></row><row><cell>Location (selected)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>At home (own or external)</cell><cell>526</cell><cell>61.1</cell><cell>252</cell><cell>38.5</cell><cell>129</cell><cell>28.4</cell><cell>907</cell><cell>46.0</cell></row><row><cell>Restaurant</cell><cell>30</cell><cell>3.5</cell><cell>28</cell><cell>4.3</cell><cell>34</cell><cell>7.5</cell><cell>92</cell><cell>4.7</cell></row><row><cell>Garden, park, countryside</cell><cell>37</cell><cell>4.3</cell><cell>149</cell><cell>22.7</cell><cell>77</cell><cell>17.0</cell><cell>263</cell><cell>13.4</cell></row><row><cell>Urban public place</cell><cell>27</cell><cell>3.1</cell><cell>31</cell><cell>4.7</cell><cell>48</cell><cell>10.6</cell><cell>106</cell><cell>5.4</cell></row><row><cell>School, work</cell><cell>82</cell><cell>9.5</cell><cell>59</cell><cell>9.0</cell><cell>45</cell><cell>9.9</cell><cell>186</cell><cell>9.4</cell></row><row><cell>Hospital, medical practice</cell><cell>71</cell><cell>8.2</cell><cell>66</cell><cell>10.1</cell><cell>38</cell><cell>8.4</cell><cell>175</cell><cell>8.9</cell></row><row><cell>Previous reaction(s), of these.</cell><cell>260</cell><cell>31.6</cell><cell>201</cell><cell>33.6</cell><cell>143</cell><cell>33.4</cell><cell>604</cell><cell>32.6</cell></row><row><cell>.milder and/or similar reaction(s)</cell><cell>10%</cell><cell></cell><cell></cell><cell>11%</cell><cell>10%</cell><cell></cell><cell cols="2">10%</cell></row><row><cell>.only similar reaction(s)</cell><cell>62%</cell><cell></cell><cell></cell><cell>47%</cell><cell>45%</cell><cell></cell><cell cols="2">53%</cell></row><row><cell>.more severe reaction(s)</cell><cell>28%</cell><cell></cell><cell></cell><cell>41%</cell><cell>45%</cell><cell></cell><cell cols="2">36%</cell></row><row><cell>.more than 1 previous reaction</cell><cell>36%</cell><cell></cell><cell></cell><cell>44%</cell><cell>54%</cell><cell></cell><cell cols="2">42%</cell></row><row><cell>.elicitor was diagnosed earlier</cell><cell>72%</cell><cell></cell><cell></cell><cell>75%</cell><cell>63%</cell><cell></cell><cell cols="2">71%</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>TABLE II .</head><label>II</label><figDesc><div><p><s>Specific elicitors by age group, suspected in parentheses (Fig 2, left panel).</s><s>The other gastrointestinal symptoms, such as abdominal pain (16%) and diarrhea (5%), occurred independently of age.</s><s>The respiratory tract was affected in 80% of patients.</s><s>Up to 55% of patients reported dyspnea, and 35% documented wheezing with similar frequencies from birth to adolescence.</s><s>Life-threatening respiratory arrest occurred in all age groups (overall n 5 15).</s><s>Only throat and chest tightness increased with age, and cough was mainly reported before approximately 10 years of age (Fig 2, central panel).</s><s>Cardiac and circulatory symptoms were less frequent (41%) and predominated by dizziness, hypotension, and collapse in adolescence (Fig 2, right panel).</s><s>There were 7 cases of cardiac arrest.</s><s>Other organ systems, mainly neurologic symptoms, were involved in 26% of the patients (eg, reduced alertness [13%]).</s></p></div></figDesc><table><row><cell></cell><cell>Preschoolers, &lt;6 y</cell><cell cols="4">Children, 6-12 y</cell><cell>Adolescents, 13-17 y</cell><cell>All</cell></row><row><cell>Total</cell><cell>861</cell><cell></cell><cell cols="2">655</cell><cell></cell><cell>454</cell><cell>1970</cell></row><row><cell>Elicitor known (suspected)</cell><cell>724 (110)</cell><cell cols="3">535 (94)</cell><cell></cell><cell>306 (100)</cell><cell>1565 (304)</cell></row><row><cell>Food</cell><cell>673 (88)</cell><cell cols="3">288 (57)</cell><cell></cell><cell>131 (54)</cell><cell>1092 (199)</cell></row><row><cell>Cashew</cell><cell>58 (8)</cell><cell></cell><cell cols="2">17</cell><cell></cell><cell>3 (1)</cell><cell>78 (9)</cell></row><row><cell>Hazelnut</cell><cell>52 (5)</cell><cell cols="3">21 (3)</cell><cell></cell><cell>3 (2)</cell><cell>76 (10)</cell></row><row><cell>Walnut</cell><cell>25 (4)</cell><cell cols="3">14 (3)</cell><cell></cell><cell>3</cell><cell>42 (7)</cell></row><row><cell>Pistachio</cell><cell>14 (1)</cell><cell></cell><cell cols="2">5 (1)</cell><cell></cell><cell>2</cell><cell>21 (2)</cell></row><row><cell>Pine nut</cell><cell>5</cell><cell></cell><cell>8</cell><cell></cell><cell></cell><cell>-</cell><cell>13</cell></row><row><cell>Other tree nuts*</cell><cell>6 (5)</cell><cell></cell><cell cols="2">9 (6)</cell><cell></cell><cell>11 (5)</cell><cell>26 (16)</cell></row><row><cell>Celery</cell><cell>-</cell><cell></cell><cell cols="2">3 (1)</cell><cell></cell><cell>5 (2)</cell><cell>8 (3)</cell></row><row><cell>Other vegetables*</cell><cell>1</cell><cell></cell><cell cols="2">6 (1)</cell><cell></cell><cell>4 (2)</cell><cell>11 (3)</cell></row><row><cell>Wheat</cell><cell>17</cell><cell></cell><cell cols="2">9 (1)</cell><cell></cell><cell>2 (2)</cell><cell>28 (3)</cell></row><row><cell>Other cereals*</cell><cell>7</cell><cell></cell><cell cols="2">4 (2)</cell><cell></cell><cell>6 (2)</cell><cell>17 (4)</cell></row><row><cell>Hen's egg</cell><cell>103 (12)</cell><cell cols="3">12 (2)</cell><cell></cell><cell>5</cell><cell>120 (14)</cell></row><row><cell>Cow's milk</cell><cell>114 (6)</cell><cell cols="3">10 (3)</cell><cell></cell><cell>4 (3)</cell><cell>128 (12)</cell></row><row><cell>Goat's milk</cell><cell>5 (1)</cell><cell></cell><cell>6</cell><cell></cell><cell></cell><cell>5 (1)</cell><cell>16 (2)</cell></row><row><cell>Shrimp</cell><cell>1 (1)</cell><cell></cell><cell cols="2">7 (2)</cell><cell></cell><cell>10 (4)</cell><cell>18 (7)</cell></row><row><cell>Codfish</cell><cell>12 (3)</cell><cell></cell><cell>4</cell><cell></cell><cell></cell><cell>1</cell><cell>17 (3)</cell></row><row><cell>Other animal products*</cell><cell>26 (3)</cell><cell cols="3">12 (1)</cell><cell></cell><cell>6 (5)</cell><cell>44 (9)</cell></row><row><cell>Peanut</cell><cell>176 (15)</cell><cell cols="3">92 (8)</cell><cell></cell><cell>29 (5)</cell><cell>297 (28)</cell></row><row><cell>Soy</cell><cell>4 (1)</cell><cell></cell><cell>7</cell><cell></cell><cell></cell><cell>6 (1)</cell><cell>17 (2)</cell></row><row><cell>Pea</cell><cell>6 (2)</cell><cell></cell><cell cols="2">3 (1)</cell><cell></cell><cell>-</cell><cell>9 (3)</cell></row><row><cell>Other legumes*</cell><cell>15 (1)</cell><cell cols="3">16 (1)</cell><cell></cell><cell>4</cell><cell>35 (2)</cell></row><row><cell>Sesame</cell><cell>8 (3)</cell><cell></cell><cell cols="2">3 (1)</cell><cell></cell><cell>4 (1)</cell><cell>15 (5)</cell></row><row><cell>Other spices*</cell><cell>5 (2)</cell><cell></cell><cell cols="2">3 (1)</cell><cell></cell><cell>4 (1)</cell><cell>12 (4)</cell></row><row><cell>Fruits*</cell><cell>8 (1)</cell><cell cols="3">15 (2)</cell><cell></cell><cell>13 (2)</cell><cell>36 (5)</cell></row><row><cell>Insects</cell><cell>31 (7)</cell><cell cols="3">194 (12)</cell><cell></cell><cell>121 (16)</cell><cell>346 (35)</cell></row><row><cell>Yellow jacket</cell><cell>12 (4)</cell><cell cols="3">98 (8)</cell><cell></cell><cell>61 (8)</cell><cell>171 (20)</cell></row><row><cell>Bee</cell><cell>17</cell><cell cols="3">84 (4)</cell><cell></cell><cell>51 (5)</cell><cell>152 (9)</cell></row><row><cell>Hornet</cell><cell>2</cell><cell></cell><cell>8</cell><cell></cell><cell></cell><cell>8</cell><cell>18</cell></row><row><cell>Drugs</cell><cell>13 (13)</cell><cell cols="3">15 (11)</cell><cell></cell><cell>27 (22)</cell><cell>55 (46)</cell></row><row><cell>Cephalosporins</cell><cell>3 (2)</cell><cell></cell><cell>6</cell><cell></cell><cell></cell><cell>(2)</cell><cell>9 (4)</cell></row><row><cell>Penicillin</cell><cell>2 (1)</cell><cell></cell><cell cols="2">2 (1)</cell><cell></cell><cell>3</cell><cell>7 (2)</cell></row><row><cell>Analgesics</cell><cell>5 (3)</cell><cell></cell><cell cols="2">5 (5)</cell><cell></cell><cell>12 (11)</cell><cell>22 (19)</cell></row><row><cell>Immunotherapy</cell><cell>-</cell><cell></cell><cell cols="2">32</cell><cell></cell><cell>18</cell><cell>50</cell></row><row><cell></cell><cell></cell><cell></cell><cell cols="2">100%</cell><cell></cell><cell>Pre-schoolers</cell><cell>Children</cell><cell>Adolescents</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Cow's</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>80%</cell><cell>milk</cell></row><row><cell></cell><cell></cell><cell>Frequency</cell><cell>(food items)</cell><cell>60% 40%</cell><cell>Hen's egg</cell><cell>Peanut Hazelnut Cashew</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>20%</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>other food items</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>0%</cell><cell></cell><cell>0%</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Yellow jacket Bee</cell><cell>AIT</cell><cell>Drugs</cell><cell>60% 40% 20%</cell><cell>Frequency</cell><cell>(non-food elicitors)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>r i b</cell><cell>h t</cell><cell>6</cell><cell>2 1</cell><cell>7 1</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Age [years]</cell></row></table><note><p><s>Rare elicitors are not reported in detail: insects (mosquito, horsefly, and bumblebee), some drugs, and latex.Numbers of highly suspected elicitors are shown in parentheses.*Othertree</s><s>nuts include almond, brazil nut, macadamia, and pecan; other vegetables include carrot, lettuce, tomato, and cabbage; other cereals include buckwheat, barley, sweet corn, rye, rice, and spelt; other animal products include chicken, beef, pork, quail's egg, ewe's milk, tuna, mackerel, zander, swai (Pangasius), salmon, pollock, trout, calamari, mussels, snails, and crab; other legumes include bean, chickpea, lupine, and lentil; other spices include curry, poppy, pepper, mustard, sunflower seed, and pumpkin seed; and fruits include pineapple, apple, banana, pear, cherry, kiwi, lychee, tangerine, mango, melon, nectarine, peach, grape, fig, and other citrus fruits.The elicitor was not specified in 101 patients.FIG 1. Elicitor of anaphylaxis by age only for known elicitors (n 5 1565).Rare elicitors were omitted (eg, other insects and latex).AIT, Allergen immunotherapy.adolescence</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>TABLE III .</head><label>III</label><figDesc><div><p><s>Emergency treatment of anaphylaxis by age group</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">Preschoolers, &lt;6 y</cell><cell cols="2">Children, 6-12 y</cell><cell>Adolescents, 13-17 y</cell><cell>All</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Number</cell><cell cols="2">Percent</cell><cell>Number</cell><cell>Percent</cell><cell>Number</cell><cell>Percent</cell><cell>Number</cell><cell>Percent</cell></row><row><cell cols="2">Total</cell><cell></cell><cell></cell><cell></cell><cell>861</cell><cell></cell><cell></cell><cell>655</cell><cell>454</cell><cell>1970</cell></row><row><cell cols="4">Lay treatment, of these.</cell><cell></cell><cell>271</cell><cell cols="2">32.7</cell><cell>193</cell><cell>30.5</cell><cell>98</cell><cell>22.6</cell><cell>562</cell><cell>29.6</cell></row><row><cell cols="3">.self-treated</cell><cell></cell><cell></cell><cell></cell><cell>3%</cell><cell></cell><cell>6%</cell><cell>37%</cell><cell>10%</cell></row><row><cell cols="4">.by nursery/schoolteacher</cell><cell></cell><cell></cell><cell>6%</cell><cell></cell><cell>5%</cell><cell>1%</cell><cell>5%</cell></row><row><cell cols="4">.epinephrine autoinjector</cell><cell></cell><cell></cell><cell>10%</cell><cell></cell><cell>13%</cell><cell>19%</cell><cell>12%</cell></row><row><cell cols="5">.autoinjector prescribed but NOT used</cell><cell></cell><cell>14%</cell><cell></cell><cell>17%</cell><cell>10%</cell><cell>14%</cell></row><row><cell cols="4">.b 2 -agonist inhaler</cell><cell></cell><cell></cell><cell>24%</cell><cell></cell><cell>36%</cell><cell>26%</cell><cell>28%</cell></row><row><cell cols="4">.antihistamine tablets</cell><cell></cell><cell></cell><cell>80%</cell><cell></cell><cell>80%</cell><cell>72%</cell><cell>78%</cell></row><row><cell cols="4">.corticosteroid tablets</cell><cell></cell><cell></cell><cell>56%</cell><cell></cell><cell>48%</cell><cell>49%</cell><cell>52%</cell></row><row><cell cols="5">Professional treatment, of these.</cell><cell>558</cell><cell cols="2">67.2</cell><cell>456</cell><cell>72.2</cell><cell>349</cell><cell>80.4</cell><cell>1363</cell><cell>71.9</cell></row><row><cell cols="4">.by emergency physician</cell><cell></cell><cell></cell><cell>39%</cell><cell></cell><cell>36%</cell><cell>42%</cell><cell>38%</cell></row><row><cell cols="4">.by allergy specialist</cell><cell></cell><cell></cell><cell>11%</cell><cell></cell><cell>12%</cell><cell>5%</cell><cell>10%</cell></row><row><cell cols="4">.epinephrine (intramuscular)</cell><cell></cell><cell></cell><cell>17%</cell><cell></cell><cell>16%</cell><cell>12%</cell><cell>15%</cell></row><row><cell cols="4">.epinephrine (intravenous)</cell><cell></cell><cell></cell><cell>5%</cell><cell></cell><cell>6%</cell><cell>11%</cell><cell>7%</cell></row><row><cell cols="4">.epinephrine (inhalation)</cell><cell></cell><cell></cell><cell>8%</cell><cell></cell><cell>8%</cell><cell>6%</cell><cell>7%</cell></row><row><cell cols="4">.epinephrine, second dose</cell><cell></cell><cell></cell><cell>10%</cell><cell></cell><cell>7%</cell><cell>10%</cell><cell>9%</cell></row><row><cell cols="4">.b 2 -agonist (inhalation)</cell><cell></cell><cell></cell><cell>20%</cell><cell></cell><cell>27%</cell><cell>23%</cell><cell>23%</cell></row><row><cell cols="4">.antihistamine (intravenous)</cell><cell></cell><cell></cell><cell>29%</cell><cell></cell><cell>55%</cell><cell>61%</cell><cell>45%</cell></row><row><cell cols="4">.antihistamine (oral)</cell><cell></cell><cell></cell><cell>42%</cell><cell></cell><cell>29%</cell><cell>20%</cell><cell>33%</cell></row><row><cell cols="4">.corticosteroid (intravenous)</cell><cell></cell><cell></cell><cell>37%</cell><cell></cell><cell>65%</cell><cell>71%</cell><cell>54%</cell></row><row><cell cols="4">.corticosteroid (oral)</cell><cell></cell><cell></cell><cell>24%</cell><cell></cell><cell>17%</cell><cell>14%</cell><cell>20%</cell></row><row><cell cols="4">.corticosteroid (rectal)</cell><cell></cell><cell></cell><cell>17%</cell><cell></cell><cell>7%</cell><cell>1%</cell><cell>10%</cell></row><row><cell cols="2">.O 2</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>8%</cell><cell></cell><cell>10%</cell><cell>11%</cell><cell>10%</cell></row><row><cell cols="2">.fluids</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>16%</cell><cell></cell><cell>25%</cell><cell>25%</cell><cell>21%</cell></row><row><cell cols="4">Second-line treatment</cell><cell></cell><cell>111</cell><cell>17.1</cell><cell></cell><cell>90</cell><cell>20.3</cell><cell>67</cell><cell>22.0</cell><cell>268</cell><cell>19.2</cell></row><row><cell cols="4">Admitted to hospital, of these.</cell><cell></cell><cell>177</cell><cell>52.2</cell><cell></cell><cell>124</cell><cell>55.1</cell><cell>93</cell><cell>56.4</cell><cell>394</cell><cell>54.0</cell></row><row><cell cols="5">.treated in intensive care unit</cell><cell></cell><cell>5%</cell><cell></cell><cell>6%</cell><cell>11%</cell><cell>6%</cell></row><row><cell></cell><cell>40%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>30%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Received epinephrine</cell><cell>20%</cell><cell>11%</cell><cell></cell><cell>12%</cell><cell cols="2">intramuscular</cell><cell>25%</cell><cell></cell></row><row><cell></cell><cell>10%</cell><cell></cell><cell></cell><cell cols="2">intravenous</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>inhala on</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>0%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell cols="2">2009</cell><cell>'10</cell><cell>'11</cell><cell>'12</cell><cell>'13</cell><cell>2014</cell><cell></cell></row><row><cell></cell><cell cols="2">n=127</cell><cell>n=148</cell><cell>n=216</cell><cell>n=200</cell><cell>n=188</cell><cell>n=207</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">Year of reac on</cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>TABLE IV .</head><label>IV</label><figDesc><div><p><s>Diagnosis and long-term management by age group</s></p></div></figDesc><table><row><cell></cell><cell cols="2">Preschoolers, &lt;6 y</cell><cell cols="2">Children, 6-12 y</cell><cell cols="2">Adolescents, 13-17 y</cell><cell>All</cell><cell></cell></row><row><cell></cell><cell>Number</cell><cell>Percent</cell><cell>Number</cell><cell>Percent</cell><cell>Number</cell><cell>Percent</cell><cell>Number</cell><cell>Percent</cell></row><row><cell>Total</cell><cell>861</cell><cell></cell><cell>655</cell><cell></cell><cell>454</cell><cell></cell><cell>1970</cell><cell></cell></row><row><cell>Elicitor confirmed by diagnostic test, of these.</cell><cell>611</cell><cell>92.2</cell><cell>396</cell><cell>87.4</cell><cell>263</cell><cell>84.6</cell><cell>1270</cell><cell>89.0</cell></row><row><cell>.already before the reported reaction</cell><cell>28%</cell><cell></cell><cell cols="2">35%</cell><cell>20%</cell><cell></cell><cell cols="2">29%</cell></row><row><cell>Skin test performed, of these.</cell><cell>559</cell><cell>70.3</cell><cell>418</cell><cell>71.7</cell><cell>291</cell><cell>74.2</cell><cell>1268</cell><cell>71.6</cell></row><row><cell>.positive</cell><cell>89%</cell><cell></cell><cell cols="2">87%</cell><cell>73%</cell><cell></cell><cell cols="2">85%</cell></row><row><cell>Intradermal test performed, of these.</cell><cell>16</cell><cell>2.6</cell><cell>58</cell><cell>14.6</cell><cell>54</cell><cell>20.5</cell><cell>128</cell><cell>10.1</cell></row><row><cell>.positive</cell><cell>63%</cell><cell></cell><cell cols="2">91%</cell><cell>83%</cell><cell></cell><cell cols="2">84%</cell></row><row><cell>Provocation performed, of these.</cell><cell>107</cell><cell>13.5</cell><cell>48</cell><cell>8.4</cell><cell>46</cell><cell>11.9</cell><cell>201</cell><cell>11.5</cell></row><row><cell>.positive</cell><cell>88%</cell><cell></cell><cell cols="2">83%</cell><cell>53%</cell><cell></cell><cell cols="2">80%</cell></row><row><cell>sIgE assessed, of these.</cell><cell>432</cell><cell>90.6</cell><cell>341</cell><cell>87.9</cell><cell>222</cell><cell>86.7</cell><cell>995</cell><cell>88.8</cell></row><row><cell>.positive</cell><cell>94%</cell><cell></cell><cell cols="2">93%</cell><cell>80%</cell><cell></cell><cell cols="2">91%</cell></row><row><cell>sIgE against recombinant allergen assessed, of these.</cell><cell>156</cell><cell>48.8</cell><cell>123</cell><cell>60.9</cell><cell>82</cell><cell>58.2</cell><cell>361</cell><cell>54.4</cell></row><row><cell>.positive</cell><cell>88%</cell><cell></cell><cell cols="2">92%</cell><cell>87%</cell><cell></cell><cell cols="2">89%</cell></row><row><cell>Tryptase assessed (baseline), of these.</cell><cell>179</cell><cell>21.8</cell><cell>246</cell><cell>38.4</cell><cell>226</cell><cell>51.6</cell><cell>651</cell><cell>34.3</cell></row><row><cell>.increased (&gt; _11.5 ng/mL)</cell><cell>10%</cell><cell></cell><cell>6%</cell><cell></cell><cell>3%</cell><cell></cell><cell>6%</cell><cell></cell></row><row><cell>Allergen immunotherapy*</cell><cell>24</cell><cell>63.2</cell><cell>150</cell><cell>73.9</cell><cell>102</cell><cell>75.0</cell><cell>276</cell><cell>73.2</cell></row><row><cell>Counseling about avoidance</cell><cell>815</cell><cell>95.3</cell><cell>574</cell><cell>88.7</cell><cell>373</cell><cell>82.7</cell><cell>1762</cell><cell>90.2</cell></row><row><cell>Training (emergency plan/drug use)</cell><cell>798</cell><cell>93.3</cell><cell>585</cell><cell>90.4</cell><cell>365</cell><cell>80.9</cell><cell>1748</cell><cell>89.5</cell></row><row><cell>Prescription of emergency drugs, of these</cell><cell>804</cell><cell>94.0</cell><cell>595</cell><cell>92.0</cell><cell>374</cell><cell>82.9</cell><cell>1773</cell><cell>90.8</cell></row><row><cell>.epinephrine autoinjector</cell><cell>88%</cell><cell></cell><cell cols="2">93%</cell><cell>91%</cell><cell></cell><cell cols="2">90%</cell></row><row><cell>.b 2 -agonist inhaler</cell><cell>33%</cell><cell></cell><cell cols="2">40%</cell><cell>27%</cell><cell></cell><cell cols="2">34%</cell></row><row><cell>.antihistamine tablets</cell><cell>98%</cell><cell></cell><cell cols="2">98%</cell><cell>98%</cell><cell></cell><cell cols="2">98%</cell></row><row><cell>.corticosteroid tablets</cell><cell>91%</cell><cell></cell><cell cols="2">91%</cell><cell>93%</cell><cell></cell><cell cols="2">91%</cell></row><row><cell>sIgE, Specific IgE.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>*Limited to cases of insect venom-induced anaphylaxis.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>TABLE V .</head><label>V</label><figDesc><div><p><s>Most severe cases in order of increasing age</s></p></div></figDesc><table><row><cell>Age</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Previous</cell></row><row><cell>(y)</cell><cell>Sex</cell><cell>Elicitor</cell><cell>Interval</cell><cell cols="2">Grade ICU</cell><cell>Symptoms</cell><cell>Treatment</cell><cell>reactions</cell><cell>Diagnosis</cell></row><row><cell>0</cell><cell cols="2">M Metamizole</cell><cell>&lt;10 min</cell><cell>IV</cell><cell cols="2">* Urticaria, cardiac</cell><cell>Professional</cell><cell>No</cell><cell>Positive skin test</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>arrest</cell><cell>(epi. i.v. atropine)</cell><cell></cell><cell>response</cell></row><row><cell>0</cell><cell cols="2">M Cow's milk</cell><cell>*</cell><cell>IV</cell><cell cols="2">No Flush, respiratory</cell><cell>Family member</cell><cell>No</cell><cell>Positive</cell></row><row><cell></cell><cell cols="2">formula</cell><cell></cell><cell></cell><cell></cell><cell>arrest</cell><cell>(antih.)</cell><cell></cell><cell>provocation</cell></row><row><cell></cell><cell cols="2">(1 cup)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>1</cell><cell cols="2">F Peanut</cell><cell>*</cell><cell>IV</cell><cell cols="2">* Urticaria, vomiting,</cell><cell>Emergency doctor</cell><cell>No</cell><cell>*</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>respiratory arrest,</cell><cell>(oral antih., rectal</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>reduced alertness</cell><cell>steroids)</cell><cell></cell></row><row><cell>2</cell><cell cols="2">M Cashew</cell><cell>*</cell><cell>IV</cell><cell cols="2">* Urticaria, vomiting/</cell><cell>Emergency doctor</cell><cell>No</cell><cell>*</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>nausea, respiratory</cell><cell>(epi. inhal., antih.</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>arrest, collapse</cell><cell>i.v. and steroids, O 2</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>and volume)</cell><cell></cell></row><row><cell>2</cell><cell cols="2">F Cashew</cell><cell>&lt;10 min (again</cell><cell>III</cell><cell cols="2">Yes Angioedema, flush,</cell><cell>Family member</cell><cell>No</cell><cell>Positive sIgE level</cell></row><row><cell></cell><cell></cell><cell></cell><cell>after 4 h)</cell><cell></cell><cell></cell><cell>respiratory</cell><cell>(antih.)</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>symptoms,</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>hypotension/</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>tachycardia</cell><cell></cell><cell></cell></row><row><cell>3</cell><cell cols="2">M Fish (fish sticks)</cell><cell>&lt;10 min</cell><cell>III</cell><cell cols="2">Yes Angioedema,</cell><cell>Family member</cell><cell>Yes (milder,</cell><cell>Positive sIgE level</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>vomiting, collapse</cell><cell>(antih. and</cell><cell>GI/skin)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>steroids), later</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>both i.v.</cell><cell></cell></row><row><cell>4</cell><cell cols="2">F Hazelnut</cell><cell>&lt;10 min</cell><cell>III</cell><cell cols="2">Yes Urticaria, flush,</cell><cell>Professional (antih.</cell><cell>Yes (milder and</cell><cell>Positive skin test</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>dyspnea, wheezing,</cell><cell>i.v. and steroids,</cell><cell>more severe, all</cell><cell>response and sIgE</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>tachycardia</cell><cell>b 2 -agonist spray)</cell><cell>organ systems)</cell><cell>level</cell></row><row><cell>4</cell><cell cols="2">F Cow's milk</cell><cell>&gt;1 h</cell><cell>III</cell><cell cols="2">Yes Urticaria, dyspnea,</cell><cell>Family member</cell><cell>Yes (&gt;2 times</cell><cell>Positive skin test</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>wheezing</cell><cell>(AAI), steroids</cell><cell>milder, skin)</cell><cell>response, sIgE</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>i.v. and i.m.</cell><cell></cell><cell>level, and</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>provocation</cell></row><row><cell>6</cell><cell cols="2">M Goat's milk</cell><cell>&lt;10 min</cell><cell>III</cell><cell cols="2">Yes Urticaria, vomiting,</cell><cell>Emergency doctor</cell><cell>No</cell><cell>Positive sIgE level</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>wheezing,</cell><cell>(epi. i.v. and</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>tachycardia</cell><cell>steroids, b 2 -agonist</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>spray, O 2 and</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>volume)</cell><cell></cell></row><row><cell>7</cell><cell cols="2">M Peanut</cell><cell>* (again after</cell><cell>IV</cell><cell cols="2">Yes Angioedema,</cell><cell>Professional</cell><cell>No</cell><cell>Positive skin test</cell></row><row><cell></cell><cell></cell><cell></cell><cell>4 h)</cell><cell></cell><cell></cell><cell>vomiting,</cell><cell>(epi. i.v., antih.,</cell><cell></cell><cell>response, sIgE</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>respiratory arrest,</cell><cell>and steroids)</cell><cell></cell><cell>level, and</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>collapse</cell><cell></cell><cell></cell><cell>provocation</cell></row><row><cell>8</cell><cell cols="2">M Cow's milk</cell><cell>*</cell><cell>IV</cell><cell cols="2">Yes Angioedema, flush,</cell><cell>Family member (AAI,</cell><cell>Yes (milder,</cell><cell>*</cell></row><row><cell></cell><cell cols="2">(1/2 cup)</cell><cell></cell><cell></cell><cell></cell><cell>respiratory arrest,</cell><cell>antih., steroids, b 2 -</cell><cell>circulatory/</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>collapse</cell><cell>agonist spray), later</cell><cell>respiratory)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>epi. i.v., O 2 and</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>volume</cell><cell></cell></row><row><cell cols="7">9 increase in intramuscular applications, probably because of M Snails &lt;10 min Fatal * Angioedema, urticaria, cough, collapse improved training and harmonized guidelines. Further collection 9 M Cow's milk (suspected) * Fatal No Respiratory and cardiac arrest of case data in this registry will allow assessment of the adherence to new guidelines or recommended treatment modalities.</cell><cell>Emergency doctor (immediate resuscitation) Teacher (AAI, b 2 -agonist spray),</cell><cell>No Yes (once)</cell><cell>* *</cell></row><row><cell cols="7">Although only very few children with severe reactions are</cell><cell>emergency doctor</cell><cell></cell></row><row><cell cols="7">expected to experience a life-threatening course of anaphylaxis,</cell><cell>(unknown)</cell><cell></cell></row><row><cell cols="4">10 this condition remains a real threat. M Hazelnut and kiwi *</cell><cell>Fatal</cell><cell cols="2">* Vomiting, respiratory</cell><cell>Professional (epi. i.v.</cell><cell>No</cell><cell>*</cell></row><row><cell></cell><cell cols="2">(suspected)</cell><cell></cell><cell></cell><cell></cell><cell>and cardiac arrest</cell><cell>and steroids, O 2</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>and volume)</cell><cell></cell></row><row><cell>11</cell><cell cols="2">M Aspirin</cell><cell>&gt;2 h (again</cell><cell>III</cell><cell cols="2">Yes Pruritus, vomiting,</cell><cell>Emergency doctor</cell><cell>No</cell><cell>Negative skin test</cell></row><row><cell></cell><cell></cell><cell></cell><cell>after 4 h)</cell><cell></cell><cell></cell><cell>throat tightness,</cell><cell>(epi. inhal., antih.</cell><cell></cell><cell>response and</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>loss of</cell><cell>i.v. and steroids, O 2</cell><cell></cell><cell>cellular</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>consciousness</cell><cell>and volume)</cell><cell></cell><cell>stimulation</cell></row><row><cell>12</cell><cell>M Bee</cell><cell></cell><cell>*</cell><cell>IV</cell><cell cols="2">* Angioedema, flush,</cell><cell>Emergency doctor</cell><cell>No</cell><cell>*</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>respiratory arrest,</cell><cell>(unknown)</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>collapse</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(Continued)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>TABLE V .</head><label>V</label><figDesc><div><p><s>(Continued)Selection criteria: known elicitor and grade III/ICU treatment or grade IV and fatal reactions.Grade: according to Ring and Messmer.Only questionnaire versions 5 and 6 (n 5 1450).Only questionnaire versions 4 to 6 (n 5 1617).</s><s>àOnly questionnaire version 6 (n 5 761).</s></p></div></figDesc><table><row><cell cols="2">Age</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Previous</cell></row><row><cell cols="2">(y)</cell><cell>Sex</cell><cell>Elicitor</cell><cell cols="2">Interval</cell><cell cols="2">Grade ICU</cell><cell>Symptoms</cell><cell cols="3">Treatment</cell><cell>reactions</cell><cell>Diagnosis</cell></row><row><cell>12</cell><cell></cell><cell>M Bee</cell><cell></cell><cell>*</cell><cell></cell><cell>III</cell><cell cols="2">Yes Urticaria, dyspnea,</cell><cell cols="3">Professional (epi. i.v.,</cell><cell>No</cell><cell>Positive skin test</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>collapse</cell><cell cols="3">antih. and steroids)</cell><cell>response and sIgE</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>level</cell></row><row><cell>13</cell><cell></cell><cell cols="2">M Brazil nut</cell><cell>&lt;10 min</cell><cell></cell><cell>III</cell><cell cols="2">Yes Angioedema,</cell><cell cols="3">Emergency doctor</cell><cell>No</cell><cell>Positive sIgE level</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>vomiting, dyspnea,</cell><cell cols="3">(epi. inhal. and</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>reduced alertness</cell><cell cols="3">b 2 -agonist inhal.,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">antih. i.v. and</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">steroids, O 2 )</cell></row><row><cell>13</cell><cell></cell><cell cols="2">M Buckwheat</cell><cell>&lt;10 min</cell><cell></cell><cell>III</cell><cell cols="2">Yes Angioedema, flush,</cell><cell cols="2">Family member</cell><cell>Yes (&gt;2 times</cell><cell>Positive skin test</cell></row><row><cell></cell><cell></cell><cell cols="2">(1 cup)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>stridor, loss of</cell><cell cols="2">(AAI, antih.,</cell><cell>milder and more</cell><cell>response and</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>consciousness</cell><cell cols="3">steroids), later epi.</cell><cell>severe, skin/</cell><cell>sIgE level</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">i.m. and i.v.,</cell><cell>circulatory/</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">b 2 -agonist spray,</cell><cell>respiratory)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">steroids i.v. and O 2</cell></row><row><cell>14</cell><cell></cell><cell cols="3">M General anesthetic &lt;10 min</cell><cell></cell><cell>IV</cell><cell cols="2">Yes Urticaria, respiratory</cell><cell cols="3">Professional (epi. i.v.,</cell><cell>No</cell><cell>*</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>arrest, tachycardia</cell><cell cols="3">antih. and steroids,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">b 2 -agonist spray,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>O 2 )</cell><cell></cell></row><row><cell>15</cell><cell></cell><cell cols="2">M Volume expander</cell><cell>*</cell><cell></cell><cell>IV</cell><cell cols="2">* Cardiac arrest</cell><cell cols="3">Professional (epi. i.v.</cell><cell>No</cell><cell>*</cell></row><row><cell></cell><cell></cell><cell cols="2">(HES)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">and steroids, b 2 -</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">agonist spray, O 2 )</cell></row><row><cell>15</cell><cell></cell><cell cols="2">F Yellow jacket</cell><cell cols="2">&lt;10 min (again</cell><cell>III</cell><cell cols="2">Yes Angioedema,</cell><cell cols="3">Emergency doctor</cell><cell>No</cell><cell>*</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">after 4 h)</cell><cell></cell><cell></cell><cell>vomiting, dyspnea,</cell><cell cols="3">(antih. i.v. and</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>collapse</cell><cell>steroids)</cell><cell></cell></row><row><cell>15</cell><cell></cell><cell cols="2">F Narcotics</cell><cell>&lt;10 min</cell><cell></cell><cell>IV</cell><cell cols="2">no Angioedema,</cell><cell cols="3">Emergency doctor</cell><cell>No</cell><cell>Positive intradermal</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>respiratory arrest,</cell><cell cols="3">(epi. i.v., antih. and</cell><cell>test response and</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>loss of</cell><cell cols="3">steroids, O 2 and</cell><cell>sIgE level</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>consciousness</cell><cell>volume)</cell><cell></cell><cell>5</cell><cell>87</cell><cell>5.4</cell></row><row><cell>16</cell><cell cols="3">M Cow's milk Tachycardia</cell><cell>&lt;10 min</cell><cell>87</cell><cell>Fatal</cell><cell cols="2">* Diarrhea, vomiting, 10.1 57</cell><cell cols="3">Family member (b 2 -8.7 52</cell><cell>Yes (milder, GI) 11.5</cell><cell>196</cell><cell>*</cell><cell>9.9</cell></row><row><cell></cell><cell cols="3">(suspected) Palpitations*</cell><cell></cell><cell>11</cell><cell></cell><cell>1.6</cell><cell>respiratory and 2</cell><cell cols="3">agonist spray), later 0.4 4</cell><cell>1.2</cell><cell>17</cell><cell>1.2</cell></row><row><cell></cell><cell cols="2">Cardiac arrest</cell><cell></cell><cell></cell><cell>1</cell><cell></cell><cell>0.1</cell><cell>cardiac arrest 3</cell><cell cols="3">epi. i.v. and steroids 0.5 3</cell><cell>0.7</cell><cell>7</cell><cell>0.4</cell></row><row><cell>17</cell><cell cols="3">F Peanut and Chest pain, angina*</cell><cell>&lt;10 min</cell><cell>0</cell><cell>Fatal</cell><cell cols="2">* Vomiting, respiratory 0.0 4</cell><cell cols="3">Emergency doctor 0.9 4</cell><cell>Yes (milder) 1.2</cell><cell>8</cell><cell>*</cell><cell>0.6</cell></row><row><cell cols="2">Other</cell><cell cols="2">chicken</cell><cell></cell><cell>239</cell><cell></cell><cell>27.8</cell><cell>and cardiac arrest 156</cell><cell>(immediate 23.8</cell><cell cols="2">117</cell><cell>25.8</cell><cell>512</cell><cell>26.0</cell></row><row><cell></cell><cell cols="3">(suspected) Reduced alertness</cell><cell></cell><cell>168</cell><cell></cell><cell>19.5</cell><cell>59</cell><cell cols="2">resuscitation) 9.0</cell><cell>36</cell><cell>7.9</cell><cell>263</cell><cell>13.4</cell></row><row><cell>17</cell><cell cols="3">M Tomato (1 plate) Sweating, trembleà</cell><cell cols="2">&gt;4 h (again 21</cell><cell>III</cell><cell cols="2">Yes Angioedema, 5.9 29</cell><cell cols="3">Emergency doctor 12.4 47</cell><cell>No</cell><cell>26.9</cell><cell>Positive skin test 97 12.7</cell></row><row><cell></cell><cell cols="2">Paresthesiaà</cell><cell></cell><cell cols="2">after 12 h) 6</cell><cell></cell><cell>1.7</cell><cell>wheezing, collapse, 15</cell><cell cols="2">(steroids i.v.) 6.4</cell><cell>15</cell><cell>8.6</cell><cell>response 36</cell><cell>4.7</cell></row><row><cell></cell><cell cols="3">Cyanosis, pallorà</cell><cell></cell><cell>54</cell><cell></cell><cell>15.3</cell><cell>tachycardia 37</cell><cell>15.9</cell><cell></cell><cell>21</cell><cell>12.0</cell><cell>112</cell><cell>14.7</cell></row><row><cell cols="3">Dysphoniaà</cell><cell></cell><cell></cell><cell>12</cell><cell></cell><cell>3.4</cell><cell>14</cell><cell>6.0</cell><cell></cell><cell>6</cell><cell>3.4</cell><cell>32</cell><cell>4.2</cell></row><row><cell cols="3">Agonyà</cell><cell></cell><cell></cell><cell>16</cell><cell></cell><cell>4.5</cell><cell>15</cell><cell>6.4</cell><cell></cell><cell>6</cell><cell>3.4</cell><cell>37</cell><cell>4.9</cell></row><row><cell cols="4">Sight disorderà</cell><cell></cell><cell>1</cell><cell></cell><cell>0.3</cell><cell>2</cell><cell>0.9</cell><cell></cell><cell>6</cell><cell>3.4</cell><cell>9</cell><cell>1.2</cell></row><row><cell cols="3">Dysarthriaà</cell><cell></cell><cell></cell><cell>4</cell><cell></cell><cell>1.1</cell><cell>4</cell><cell>1.7</cell><cell></cell><cell>2</cell><cell>1.1</cell><cell>10</cell><cell>1.3</cell></row><row><cell cols="4">Severity grading (Ring)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">I (skin only)</cell><cell></cell><cell></cell><cell>73</cell><cell></cell><cell>8.5</cell><cell>39</cell><cell>6.0</cell><cell></cell><cell>20</cell><cell>4.4</cell><cell>132</cell><cell>6.7</cell></row><row><cell cols="4">II (2nd organ system mild)</cell><cell></cell><cell>316</cell><cell></cell><cell>36.8</cell><cell>315</cell><cell>48.2</cell><cell cols="2">260</cell><cell>57.5</cell><cell>891</cell><cell>45.3</cell></row><row><cell cols="4">III (2nd organ system severe)</cell><cell></cell><cell>464</cell><cell></cell><cell>54.0</cell><cell>294</cell><cell>45.0</cell><cell cols="2">166</cell><cell>36.7</cell><cell>924</cell><cell>47.0</cell></row><row><cell cols="4">IV (cardiac/respiratory arrest)</cell><cell></cell><cell>6</cell><cell></cell><cell>0.7</cell><cell>6</cell><cell>0.9</cell><cell></cell><cell>6</cell><cell>1.3</cell><cell>18</cell><cell>0.9</cell></row><row><cell cols="4">Biphasic, of these.</cell><cell></cell><cell>30</cell><cell></cell><cell>4.2</cell><cell>30</cell><cell>6.0</cell><cell></cell><cell>17</cell><cell>5.0</cell><cell>77</cell><cell>5.0</cell></row><row><cell cols="4">.after more than 12 h</cell><cell></cell><cell></cell><cell>23%</cell><cell></cell><cell>50%</cell><cell></cell><cell></cell><cell>63%</cell><cell>42%</cell></row></table><note><p><s>23AAI, Epinephrine autoinjector; antih., antihistamine; epi., epinephrine; GI, gastrointestinal; ICU, intensive care unit; i.m., intramuscular; inhal., inhalation; i.v., intravenous; sIgE, specific IgE.</s><s>*Not documented, no data available.</s><s>10.*</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">J ALLERGYCLIN IMMUNOL  VOLUME 137, NUMBER 4   </note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">J ALLERGYCLIN IMMUNOL  APRIL 2016   </note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">J ALLERGY CLIN IMMUNOL</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>We thank all the families and their children for their support of this study in providing data on the occurrence of anaphylaxis.</s><s>We thank the study personnel for family counseling and data entry: E.-M.</s><s>Varga, W. Aberer (Graz, Austria); N. Reider (Innsbruck, Austria); J. Aub€ ock, B. Zahel, C. Scheurecker (Linz, Austria); I. Hutteger, T. Hawranek (Salzburg, Austria); F. Eitelberger, B. Wintersteiger (Wels, Austria); Z. Szepfalusi, W. Emminger, T. Kinaciyan (Wien, Austria); G. Christoff (Sofia, Bulgaria); K. Tenbrock, S. Lehmann, F.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Key messages</head><p><s>d Foods dominate as elicitors of anaphylaxis in the first decade of life and are then continuously replaced by insect venom and drugs.</s></p><p><s>d About one in 100 children reporting severe anaphylaxis experienced a life-threatening or fatal reaction.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title/>
		<author>
			<persName><surname>Friedrichs</surname></persName>
		</author>
		<imprint>
			<pubPlace>Aachen, Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">U</forename><surname>Wienke-Graul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Plank-Habibi</surname></persName>
		</author>
		<imprint>
			<pubPlace>Alzenau, Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Gerstlauer</surname></persName>
		</author>
		<imprint>
			<pubPlace>Augsburg, Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">B</forename><surname>Niggemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Klettke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Staden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hompes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Scholz</surname></persName>
		</author>
		<imprint>
			<pubPlace>Berlin, Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">C</forename><surname>Koerner-Rettberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Dickel</surname></persName>
		</author>
		<imprint>
			<pubPlace>Bochum, Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">S</forename><surname>Gernert</surname></persName>
		</author>
		<imprint>
			<pubPlace>Bonn, Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">H</forename><surname>Straube</surname></persName>
		</author>
		<imprint>
			<pubPlace>Darmstadt, Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">K</forename><surname>End</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nordwig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Vogelberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bauer</surname></persName>
		</author>
		<imprint>
			<pubPlace>Dresden, Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">S</forename><surname>Schweitzer-Krantz</surname></persName>
		</author>
		<imprint>
			<publisher>D€ usseldorf</publisher>
			<pubPlace>Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">S</forename><surname>Miroslau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Schinkel</surname></persName>
		</author>
		<imprint>
			<pubPlace>Eberswalde, Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">V</forename><surname>Mahler</surname></persName>
		</author>
		<imprint>
			<pubPlace>Erlangen, Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">U</forename><surname>Hillen</surname></persName>
		</author>
		<imprint>
			<pubPlace>Essen, Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Brandes</surname></persName>
		</author>
		<imprint>
			<pubPlace>Frankfurt/Oder, Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">A</forename><surname>Heinzmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Jakob</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fabian</surname></persName>
		</author>
		<imprint>
			<pubPlace>Freiburg, Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<monogr>
		<title level="m" type="main">Neust€ adter (F€ urth</title>
		<author>
			<persName><forename type="first">J</forename><surname>Klinge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename></persName>
		</author>
		<imprint>
			<pubPlace>Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">T</forename><surname>Fuchs</surname></persName>
			<affiliation>
				<orgName type="collaboration">G€ ottingen</orgName>
			</affiliation>
		</author>
		<imprint>
			<pubPlace>Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">R</forename><surname>Adamczewski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Bauhaus</surname></persName>
		</author>
		<imprint>
			<pubPlace>Germany</pubPlace>
		</imprint>
	</monogr>
	<note type="report_type">Graal-M€ uritz</note>
</biblStruct>

<biblStruct xml:id="b17">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">R</forename><surname>Bruns</surname></persName>
		</author>
		<imprint>
			<pubPlace>Greifswald, Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Marsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kreft</surname></persName>
		</author>
		<imprint>
			<pubPlace>Halle, Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">K</forename><surname>Breuer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Witte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Coors</surname></persName>
		</author>
		<imprint>
			<pubPlace>Hamburg, Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">G</forename><surname>Hansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Schwerk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Arens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Buck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>B€ Usselberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wedi</surname></persName>
		</author>
		<imprint>
			<pubPlace>Hannover, Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
		<imprint>
			<pubPlace>Heidelberg, Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">C</forename><surname>Pf€</surname></persName>
		</author>
		<imprint>
			<pubPlace>Homburg/Saar, Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Rett</surname></persName>
		</author>
		<imprint>
			<pubPlace>Itzehoe, Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">A</forename><surname>Reißig</surname></persName>
		</author>
		<imprint>
			<pubPlace>Jena, Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">E</forename><surname>Rietschel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Hunzelmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Siebenhaar</surname></persName>
		</author>
		<imprint>
			<publisher>K€ oln</publisher>
			<pubPlace>Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">U</forename><surname>Miehe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Prenzel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Treudler</surname></persName>
		</author>
		<imprint>
			<pubPlace>Leipzig, Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Kopp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Stichtenoth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Jappe</surname></persName>
		</author>
		<imprint>
			<publisher>L€ ubeck</publisher>
			<pubPlace>Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">B</forename><surname>Przybilla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wandschneider</surname></persName>
		</author>
		<imprint>
			<publisher>M€ unchen</publisher>
			<pubPlace>Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">I</forename><surname>Yildiz</surname></persName>
		</author>
		<imprint>
			<publisher>Neum€ unster</publisher>
			<pubPlace>Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">S</forename><surname>Volkmuth</surname></persName>
		</author>
		<imprint>
			<pubPlace>Niederberg, Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">F</forename><surname>Kn€</surname></persName>
		</author>
		<imprint>
			<pubPlace>Norderney, Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">J</forename><surname>Seidenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Haak</surname></persName>
		</author>
		<imprint>
			<pubPlace>Oldenburg, Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">S</forename><surname>B€</surname></persName>
		</author>
		<imprint>
			<pubPlace>Osnabr€ uck, Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">B</forename><surname>Schilling</surname></persName>
		</author>
		<imprint>
			<pubPlace>Passau, Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Polz</surname></persName>
			<affiliation>
				<orgName type="collaboration">R€ usselsheim</orgName>
			</affiliation>
		</author>
		<imprint>
			<pubPlace>Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">F</forename><surname>Riffelmann</surname></persName>
		</author>
		<imprint>
			<pubPlace>Schmallenberg, Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">U</forename><surname>Rabe</surname></persName>
		</author>
		<imprint>
			<pubPlace>Treuenbrietzen, Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">H</forename><surname>Rebmann</surname></persName>
			<affiliation>
				<orgName type="collaboration">T€ ubingen</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fischer</surname></persName>
			<affiliation>
				<orgName type="collaboration">T€ ubingen</orgName>
			</affiliation>
		</author>
		<imprint>
			<pubPlace>Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">W</forename><surname>Brosi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">W€ urzburg</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">L</forename><surname>Marinangeli</surname></persName>
		</author>
		<imprint>
			<pubPlace>Ancona, Italy</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">B</forename><surname>Bienkiewicz</surname></persName>
		</author>
		<imprint>
			<pubPlace>Lodz, Poland</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">I</forename><surname>Poziomkowska-Ge ˛sicka</surname></persName>
		</author>
		<imprint>
			<pubPlace>Szczecin, Poland</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Castro</surname></persName>
		</author>
		<imprint>
			<pubPlace>Guadalajara, Spain</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Francisco</surname></persName>
		</author>
		<imprint>
			<pubPlace>Madrid, Spain</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">E G</forename><surname>Figueroa</surname></persName>
		</author>
		<imprint>
			<pubPlace>Pamplona, Spain</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Higuero</surname></persName>
		</author>
		<imprint>
			<pubPlace>Toledo, Spain</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">P</forename><surname>Eng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Enriquez</surname></persName>
		</author>
		<imprint>
			<pubPlace>Aarau, Switzerland</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Bircher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Lorenzo</surname></persName>
		</author>
		<imprint>
			<pubPlace>Basel, Switzerland</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Hitzler</surname></persName>
		</author>
		<imprint>
			<pubPlace>Lucerne, Switzerland</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<monogr>
		<title level="m" type="main">We thank The Irish Paediatric Surveillance Unit (IPSU) for support in case ascertainment</title>
		<author>
			<persName><forename type="first">P</forename><surname>Schmid-Grendelmeier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Guggenheim (z€ Urich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">)</forename><surname>Switzerland</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">E</forename><surname>Simons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">R</forename><surname>Ardusso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Bil O</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Cardona</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ebisawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">M</forename><surname>El-Gamal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">International consensus on (ICON) anaphylaxis. World Allergy Organ J</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">9</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology</title>
		<author>
			<persName><forename type="first">A</forename><surname>Muraro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Roberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Worm</surname></persName>
		</author>
		<author>
			<persName><surname>Bil O Mb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Brockow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Fern</forename><surname>Rivas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="1026" to="1045" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Sampson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Muñoz-Furlong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Campbell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">F</forename><surname>Adkinson</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Bock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Branum</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="391" to="397" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Anaphylaxis: unique aspects of clinical diagnosis and management in infants (birth to age 2 years)</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">E</forename><surname>Simons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Sampson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">135</biblScope>
			<biblScope unit="page" from="1125" to="1131" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">The management of anaphylaxis in childhood: position paper of the European Academy of Allergology and Clinical Immunology</title>
		<author>
			<persName><forename type="first">A</forename><surname>Muraro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Roberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Clark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Eigenmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Halken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Lack</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="857" to="871" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Anaphylaxis in infants: can recognition and management be improved?</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">E</forename><surname>Simons</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="page" from="537" to="540" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Anaphylaxis epidemic: fact or fiction?</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">E</forename><surname>Simons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Sampson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page" from="1166" to="1168" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Wood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Camargo</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lieberman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Sampson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Schwartz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zitt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">133</biblScope>
			<biblScope unit="page" from="461" to="467" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">The epidemiology of anaphylaxis in Europe: a systematic review</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Panesar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Javad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>De Silva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">I</forename><surname>Nwaru</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hickstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Muraro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="1353" to="1361" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Epidemiology of anaphylaxis</title>
		<author>
			<persName><forename type="first">Tejedor</forename><surname>Alonso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Moro</forename><surname>Moro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Mugica</forename><surname>Garcia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Allergy</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="1027" to="1039" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Increasing anaphylaxis hospitalizations in the first 2 decades of life</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">Y</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">N</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Nurruzzaman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Allergy Asthma Immunol</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="page" from="387" to="393" />
			<date type="published" when="1990">1990-2006. 2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Increasing rate of hospitalizations for food-induced anaphylaxis in Italian children: an analysis of the Italian Ministry of Health database</title>
		<author>
			<persName><forename type="first">R</forename><surname>Nocerino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Leone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Cosenza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Berni</forename><surname>Canani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">135</biblScope>
			<biblScope unit="page" from="833" to="835" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>e3</note>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Anaphylaxis in a New York City pediatric emergency department: triggers, treatments, and outcomes</title>
		<author>
			<persName><forename type="first">F</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Chawla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>J€ Arvinen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nowak-We ˛grzyn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="page" from="e1" to="3" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Management of anaphylaxis: a systematic review</title>
		<author>
			<persName><forename type="first">S</forename><surname>Dhami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Panesar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Roberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Muraro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Worm</surname></persName>
		</author>
		<author>
			<persName><surname>Bil O Mb</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="168" to="175" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Emergency treatment of anaphylaxis in infants and children</title>
		<author>
			<persName><forename type="first">A</forename><surname>Cheng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Paediatr Child Health</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="35" to="40" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Adrenaline auto-injectors for the treatment of anaphylaxis with and without cardiovascular collapse in the community</title>
		<author>
			<persName><forename type="first">A</forename><surname>Sheikh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">E</forename><surname>Simons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Barbour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Worth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cochrane Database Syst Rev</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">D008935</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Anaphylaxis treatment: current barriers to adrenaline auto-injector use</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">T</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Worm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lieberman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="983" to="991" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Implementation of anaphylaxis management guidelines: a register-based study</title>
		<author>
			<persName><forename type="first">L</forename><surname>Grabenhenrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hompes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Gough</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ru€ Eff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Scherer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Pf€ Ohler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">e35778</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">First European data from the network of severe allergic reactions (NORA)</title>
		<author>
			<persName><forename type="first">M</forename><surname>Worm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Moneret-Vautrin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Scherer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Lang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fernandez-Rivas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Cardona</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="1397" to="1404" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Symptom profile and risk factors of anaphylaxis in Central Europe</title>
		<author>
			<persName><forename type="first">M</forename><surname>Worm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Edenharter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ru€ Eff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Scherer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Pf€ Ohler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Mahler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="691" to="698" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Triggers and treatment of anaphylaxis: an analysis of 4,000 cases from Germany, Austria and Switzerland</title>
		<author>
			<persName><forename type="first">M</forename><surname>Worm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Eckermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>D€ Olle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Aberer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Beyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hawranek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dtsch Arztebl Int</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="page" from="367" to="375" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">Towards a European registry of severe allergic reactions: current status of national registries and future needs</title>
		<author>
			<persName><forename type="first">M</forename><surname>Worm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Timmermans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Moneret-Vautrin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Muraro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">I</forename><surname>Malmheden Yman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>L€ Ovik</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="671" to="680" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">Incidence and severity of anaphylactoid reactions to colloid volume substitutes</title>
		<author>
			<persName><forename type="first">J</forename><surname>Ring</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Messmer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="466" to="469" />
			<date type="published" when="1977">1977</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">Gender differences in prevalence, diagnosis and incidence of allergic and non-allergic asthma: a population-based cohort</title>
		<author>
			<persName><forename type="first">B</forename><surname>Leynaert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sunyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Garcia-Esteban</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Svanes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Jarvis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Cerveri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Thorax</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="625" to="631" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">Age-related differences in the clinical presentation of food-induced anaphylaxis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Rudders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Banerji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Clark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Camargo</surname></persName>
		</author>
		<author>
			<persName><surname>Jr</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pediatr</title>
		<imprint>
			<biblScope unit="volume">158</biblScope>
			<biblScope unit="page" from="326" to="328" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">Anaphylaxis in the community: learning from the survivors</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">E</forename><surname>Simons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Clark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Camargo</surname><genName>Jr</genName></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="page" from="301" to="306" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">Sublingual diffusion of epinephrine microcrystals from rapidly disintegrating tablets for the potential first-aid treatment of anaphylaxis: in vitro and ex vivo study</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Rawas-Qalaji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Werdy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Rachid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">E</forename><surname>Simons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Simons</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">AAPS PharmSciTech</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="1203" to="1212" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
